Roivant Sciences Ltd. ROIV
Institutional shares held
505 Million
573K
calls
739K
puts
Total value of holdings
$5.12B
$5.82M
calls
$7.5M
puts
Market Cap
$7.15B
704,382,976
Shares Out.
Institutional ownership
71.68%
# of Institutions
328
We take great care to ensure that the data presented and summarized in this overview for Roivant Sciences Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ROIV
View all-
Qvt Financial LP New York, NY65.8MShares$668 Million76.3% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X062.1MShares$630 Million6.45% of portfolio
-
Viking Global Investors LP47.8MShares$485 Million1.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA44.1MShares$447 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$359 Million0.01% of portfolio
-
Morgan Stanley New York, NY34.6MShares$351 Million0.03% of portfolio
-
State Street Corp Boston, MA20.8MShares$211 Million0.01% of portfolio
-
Rubric Capital Management LP New York, NY20MShares$203 Million3.91% of portfolio
-
Patient Square Capital LP Menlo Park, CA12.5MShares$127 Million55.22% of portfolio
-
Two Seas Capital LP Rye, NY10.2MShares$103 Million19.7% of portfolio
Latest Institutional Activity in ROIV
Top Purchases
Top Sells
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Transactions at ROIV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 17
2025
|
Ilan Oren |
SELL
Payment of exercise price or tax liability
|
Direct |
64
-0.06%
|
$640
$10.15 P/Share
|
|
Apr 17
2025
|
Ilan Oren |
BUY
Grant, award, or other acquisition
|
Direct |
2,635
+2.5%
|
-
|
|
Apr 17
2025
|
James C Momtazee |
SELL
Payment of exercise price or tax liability
|
Direct |
276
-0.29%
|
$2,760
$10.15 P/Share
|
|
Apr 17
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
1,379
+1.42%
|
-
|
|
Apr 17
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
1,847
+4.27%
|
-
|
|
Mar 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,653
-0.62%
|
$16,530
$10.38 P/Share
|
|
Mar 24
2025
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
434,478
-27.82%
|
$4,344,780
$10.82 P/Share
|
|
Mar 24
2025
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
602,311
+27.83%
|
$1,806,933
$3.85 P/Share
|
|
Mar 20
2025
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
315,522
-24.75%
|
$3,470,742
$11.06 P/Share
|
|
Mar 20
2025
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
400,000
+23.88%
|
$1,200,000
$3.85 P/Share
|
|
Mar 20
2025
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-1.24%
|
$109,450
$10.97 P/Share
|
|
Mar 20
2025
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-0.06%
|
$109,450
$10.97 P/Share
|
|
Mar 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,504
-0.56%
|
$15,040
$10.97 P/Share
|
|
Mar 20
2025
|
Jennifer Humes Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,255
+50.0%
|
-
|
|
Feb 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,635
-0.6%
|
$16,350
$10.74 P/Share
|
|
Feb 20
2025
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-1.22%
|
$109,450
$10.72 P/Share
|
|
Feb 20
2025
|
Eric Venker President & COO |
SELL
Open market or private sale
|
Direct |
100,000
-10.03%
|
$1,000,000
$10.65 P/Share
|
|
Feb 20
2025
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+9.12%
|
$300,000
$3.85 P/Share
|
|
Feb 20
2025
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,945
-0.06%
|
$109,450
$10.72 P/Share
|
|
Feb 20
2025
|
Rakhi Kumar Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
958
-0.59%
|
$9,580
$10.72 P/Share
|
Last 12 Months Summary
Buy / Acquisition
55.7M
Shares
From
15
Insiders
| Grant, award, or other acquisition | 36.5M shares |
|---|---|
| Exercise of conversion of derivative security | 5.89M shares |
| Bona fide gift | 13.4M shares |
Sell / Disposition
29.5M
Shares
From
23
Insiders
| Payment of exercise price or tax liability | 296K shares |
|---|---|
| Other acquisition or disposition | 4.16M shares |
| Open market or private sale | 11.7M shares |
| Bona fide gift | 13.4M shares |